About
About HYPHENS PHARMA INTL LIMITED
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals. The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.
Visit company website
5 years, 6 months ago
Hyphens Pharma International Limited is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 91.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Hyphens Pharma International Limited's total revenue sank by 6.5% to $31M since the same quarter in the previous year.
Its net income has dropped by 37.8% to $1M since the same quarter in the previous year.
Finally, its free cash flow fell by 20.0% to $2M since the same quarter in the previous year.
Based on the above factors, Hyphens Pharma International Limited gets an overall score of 1/5.